We describe the synthesis and optimisation of a series of new inhibitors of BRAF, a kinase whose mutant form (V600E) is implicated in several types of cancer, with particularly high frequency in melanoma. We designed and synthesised type II inhibitors interacting with the inactive conformation of the V600EBRAF
SummaryUnresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, t...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
BRAFV600E is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targ...
We describe the synthesis and optimisation of a series of new inhibitors of BRAF, a kinase whose mut...
The BRAF oncoprotein is mutated in about half of malignant melanomas and other cancers, and a kinase...
ABSTRACT: Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human...
BRAF, a serine/threonine specific protein kinase that is part of the MAPK pathway and acts as a down...
BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that sends a sig...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
The RAS-RAF-MEK-ERK pathway is hyperactivated in 30% of human cancers. BRAF is a serine-threonine ki...
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase ...
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
BRAF is a serine/threonine kinase that is mutated in a range of cancers, including 50-70% of melanom...
We describe the design, synthesis, and optimization of a series of new inhibitors of V-RAF murine sa...
The Cancer Genome Project has identified several oncogenic mutations in BRAF that represent importan...
SummaryUnresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, t...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
BRAFV600E is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targ...
We describe the synthesis and optimisation of a series of new inhibitors of BRAF, a kinase whose mut...
The BRAF oncoprotein is mutated in about half of malignant melanomas and other cancers, and a kinase...
ABSTRACT: Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human...
BRAF, a serine/threonine specific protein kinase that is part of the MAPK pathway and acts as a down...
BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that sends a sig...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
The RAS-RAF-MEK-ERK pathway is hyperactivated in 30% of human cancers. BRAF is a serine-threonine ki...
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase ...
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of mela...
BRAF is a serine/threonine kinase that is mutated in a range of cancers, including 50-70% of melanom...
We describe the design, synthesis, and optimization of a series of new inhibitors of V-RAF murine sa...
The Cancer Genome Project has identified several oncogenic mutations in BRAF that represent importan...
SummaryUnresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, t...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
BRAFV600E is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targ...